Compare Amgen, Inc. (AMGN) vs ProShares UltraShort Bloomberg Natural Gas ETF (KOLD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amgen, Inc. vs ProShares UltraShort Bloomberg Natural Gas ETF — how do they compare? Amgen, Inc. trades at $362.14 (market cap $196.12B), while ProShares UltraShort Bloomberg Natural Gas ETF trades at $27.86. The key difference: Amgen, Inc. pays a 2.77% dividend while ProShares UltraShort Bloomberg Natural Gas ETF pays none, and Amgen, Inc. is trading nearer its 52-week high, ProShares UltraShort Bloomberg Natural Gas ETF nearer its low. Which is the better fit depends on your goals.
| AMGN | KOLD | |
|---|---|---|
Market Cap | $196.12B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $388.16 | $49.39 |
52-Week Low | $271.18 | $13.58 |
Enterprise Value | $241.41B | — |
Dividend Yield | 2.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
KOLD is trading at $26.96, up 4.25% with a bullish technical signal supported by moving averages. The stock faces resistance at $27-$29 while finding support at $25-$23 levels. Recent natural gas market volatility driven by weather patterns and LNG demand creates trading opportunities for this bearish natural gas ETF. The RSI at 73.40 indicates potential overbought conditions near-term.
As a tactical trading instrument, KOLD offers exposure to inverse natural gas price movements amid heightened energy market volatility. Key catalysts include weather-driven demand shifts and geopolitical developments affecting LNG exports. Risk factors include sudden natural gas price spikes and changing supply-demand dynamics that could pressure the fund's inverse positioning.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About ProShares UltraShort Bloomberg Natural Gas ETF
KOLD is an inverse leveraged ETF that seeks to provide two times (2x) the inverse daily performance of the Bloomberg Natural Gas Subindex. It is designed for investors looking to profit from falling natural gas prices.
Read more on KOLD →
